Subacute cutaneous lupus erythematosus-like drug eruption after durvalumab treatment for squamous cell carcinoma

Cutaneous immune-related adverse events are increasingly reported with the expanding use of immune checkpoint inhibitors to treat various cancers. A subacute cutaneous lupus erythematosus-like drug eruption was observed in a patient with durvalumab infusion, with increasing severity after each dose. The eruption improved with cessation of durvalumab, hydroxychloroquine therapy, and sun protection.